RXFP4 and nasopharyngeal carcinoma: Additionally, when we use a GPCR142 antibody to block the binding of INSL5 and GPCR142, it also diminished INSL5 oncogenic function (Fig EV5B), which indicated that GPCR142 antibody can be potential therapeutic strategy for NPC.